Integra Lifesciences Holdings (IART) Research & Development (2009 - 2026)

Integra Lifesciences Holdings has reported Research & Development for 18 years, with the latest figure at $24.3 million in Q2 2026.

• Quarterly Research & Development fell 10.16% year-over-year to $24.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $95.0 million (down 13.93% YoY) and the FY2025 annual result came in at $99.0 million, down 14.22% from the prior year.
• Research & Development grew to $24.3 million in Q2 2026 per IART's latest filing, from $23.5 million in the prior quarter.
• Over five years, Research & Development peaked at $31.2 million in Q4 2024 and troughed at $22.5 million in Q3 2025.
• A 5-year average of $26.0 million and a median of $26.1 million in 2022 frame the typical range for Research & Development.
• The sharpest annual moves came in 2024 and 2025: Research & Development increased 28.52% in 2024, then slipped 20.57% in 2025.
• Over 5 years, Research & Development stood at $26.8 million in 2022, then retreated by 9.33% to $24.3 million in 2023, then advanced by 28.52% to $31.2 million in 2024, then dropped by 20.57% to $24.8 million in 2025, then retreated by 2.17% to $24.3 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $24.3 million, $23.5 million, and $24.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.